Journal: Nanoscale Advances

Article Title: Bis-prodrug cryopreserved lipid nanoparticles with enzymatically triggered release

doi: 10.1039/d5na00675a

Figure Lengend Snippet: Effect of cryoprotectant concentration on the formulations of tricaprin at 14 wt% with varied in pegylated/unpegylated lipid surfactant blends after freeze–thaw on Day 2 after formulation. (A) Photos of each formulation before freeze thaw and after freeze thaw with different concentrations of cryoprotectant (no cryoprotectant, 1, 5 and 10% w/sucrose). (B) The z-average diameter and PDI of each of the samples as measured by DLS at ∼0.58 mg mL −1 excluding sucrose.

Article Snippet: Tricaprin was purchased from Tokyo chemical industry and used as received.

Techniques: Concentration Assay, Formulation

Journal: Nanoscale Advances

Article Title: Bis-prodrug cryopreserved lipid nanoparticles with enzymatically triggered release

doi: 10.1039/d5na00675a

Figure Lengend Snippet: Effect of cryoprotectant concentration and surfactant composition on appearance of the formulations after freeze–drying and after redispersion samples were freeze-dried on Day 2 after formulation. (A) Photos of each formulation's cake once freeze-dried with different concentrations of cryoprotectant (sucrose) as well as surfactant composition. (B) Photos of each of the same formulation before and after lyophilization. (C) Z-average diameter, and PDI obtained by DLS. All formulations contained tricaprin at 14 wt% with varied in pegylated/unpegylated lipid surfactant blends on a mass ratio. Measurements made at a fixed position of 4.65 mm in the DLS at ∼0.58 mg mL −1 excluding sucrose.

Article Snippet: Tricaprin was purchased from Tokyo chemical industry and used as received.

Techniques: Concentration Assay, Formulation, Lyophilization

Journal: Nanoscale Advances

Article Title: Bis-prodrug cryopreserved lipid nanoparticles with enzymatically triggered release

doi: 10.1039/d5na00675a

Figure Lengend Snippet: Characterisation of the formulations of tricaprin at 33 wt% varied in pegylated/unpegylated lipid surfactant blends on a mass ratio. (A) Z-average particle diameter and PDI of the different surfactant formulations, prefreezing, after freeze thaw, and after freeze drying and redispersion as measured by DLS with 10% w/v of sucrose cryoprotectant. (B) Z-average particle diameter and PDI as measured by DLS and formulations made of dodecyl prodrug/tricaprin blends at an overall 33 wt% varied in pegylated/unpegylated lipid surfactant blends on a mass ratio. (C and D) CryoSEM images of the formulation at 33 wt% with a core composition of 50/50, 3 : 1, while also in the presence of 10% w/v sucrose. Before freeze drying (C) and redispersed after freeze drying (D).

Article Snippet: Tricaprin was purchased from Tokyo chemical industry and used as received.

Techniques: Formulation